ALX ONCOLOGY HOLDINGS INC
Income Statement
| Line Item | Jun 2020 | Mar 2020 | Sep 2019 | Jun 2019 |
|---|---|---|---|---|
| Revenue | $527.0K | $655.0K | $1.3M | $1.3M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $7.7M | $3.8M | $2.2M | $3.6M |
| SG&A Expense | $3.2M | $1.5M | $938.0K | $679.0K |
| Operating Income | $-10.8M | $-5.2M | $-3.0M | $-4.2M |
| Operating Margin | -2,046.9% | -800.3% | -241.6% | -323.5% |
| Interest Expense | $200.0K | — | — | — |
| Pretax Income | $-11.3M | $-5.5M | $-3.0M | $-4.2M |
| Income Tax Expense | $20.0K | $4.0K | $8.0K | $8.0K |
| Net Income | $-11.3M | $-5.5M | $-3.0M | $-4.2M |
| Net Margin | -2,150.1% | -832.7% | -242.4% | -324.1% |
| EPS (Basic) | $-0.37 | $-0.20 | $-0.11 | $-0.14 |
| EPS (Diluted) | $-0.37 | $-0.20 | $-0.11 | $-0.14 |
| Shares Outstanding (Basic) | 38.0M | 37.7M | 37.2M | 37.0M |
| Shares Outstanding (Diluted) | 38.0M | 37.7M | 37.2M | 37.0M |
| Dividends Per Share | — | — | — | — |